Maze Therapeutics develops precision medicines by leveraging human genetics to target the underlying drivers of common diseases with significant unmet needs. The company utilizes its Compass platform for variant functionalization to design therapeutics that mimic protective genetic variants. Its current pipeline focuses on developing treatments for chronic kidney disease, including APOL1-mediated kidney disease.
Funding
$115M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
DTFLFounders
Product
Problem
Chronic kidney disease (CKD) affects millions worldwide, often progressing silently and leading to irreversible damage. Current treatments primarily manage symptoms but do not address the underlying genetic drivers of disease progression, leaving a significant unmet need for targeted therapies. APOL1 kidney disease (AKD) is a genetically-defined form of CKD with a particularly aggressive course.
Solution
Maze Therapeutics is developing precision medicines that target the genetic drivers of kidney disease, specifically focusing on APOL1 kidney disease. The company's approach involves identifying and mimicking the effects of rare, naturally occurring protective genetic variants to halt the progression and potentially reverse the effects of kidney disease. By leveraging advancements in human genetics, variant functionalization, and therapeutic discovery, Maze aims to create breakthrough treatments that address the root causes of CKD and improve patient outcomes. Their lead program, MZE829, is currently in clinical development.
Target Audience
The primary target audience includes patients with chronic kidney disease, particularly those with APOL1 kidney disease, as well as nephrologists and other healthcare providers involved in the management of CKD.
Features
- Focus on precision medicine approach targeting genetically defined forms of kidney disease.
- Development of therapies that mimic naturally occurring protective genetic variants.
- Lead program, MZE829, targeting APOL1 kidney disease.
- Utilizes advancements in human genetics, variant functionalization, and therapeutic discovery.
- Aims to halt the progression and potentially reverse the effects of kidney disease.